Wegovy Cuts Heart Attack, Stroke Risk 20% in Five-Year Trial
Enrolling 17,604 overweight adults aged 45 and over with established cardiovascular disease, Novo Nordisk’s five-year trial of Wegovy (semaglutide) for weight loss showed a 20 percent reduction in major adverse…